Acquisition by Karen Shoos of 2000 shares of Celldex Therapeutics subject to Rule 16b-3

CLDX Stock  USD 27.02  0.80  3.05%   
Slightly above 52% of Celldex Therapeutics' investor base is interested to short. The analysis of the overall investor sentiment regarding Celldex Therapeutics suggests that many traders are impartial. Celldex Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Celldex Therapeutics' earnings reports, geopolitical events, and overall market trends.
  
Filed transaction by Celldex Therapeutics Inc director. Grant, award or other acquisition pursuant to Rule 16b-3

Read at macroaxis.com
Celldex insider trading alert for grant of common stock by Karen Shoos, the corporate stakeholder, on 1st of July 2023. This event was filed by Celldex Therapeutics Inc with SEC on 2012-06-21. Statement of changes in beneficial ownership - SEC Form 4

Cash Flow Correlation

Celldex Therapeutics' cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Celldex Therapeutics' relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.
Click cells to compare fundamentals

Celldex Therapeutics Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Celldex Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Celldex Therapeutics Historical Investor Sentiment

Investor biases related to Celldex Therapeutics' public news can be used to forecast risks associated with an investment in Celldex. The trend in average sentiment can be used to explain how an investor holding Celldex can time the market purely based on public headlines and social activities around Celldex Therapeutics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Celldex Therapeutics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Celldex Therapeutics and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Celldex Therapeutics news discussions. The higher the estimate score, the more favorable the investor's outlook on Celldex Therapeutics.

Celldex Therapeutics Fundamental Analysis

We analyze Celldex Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Celldex Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Celldex Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Current Asset

Current Asset Comparative Analysis

Celldex Therapeutics is currently under evaluation in current asset category among its peers. Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.

Celldex Therapeutics Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Celldex Therapeutics stock to make a market-neutral strategy. Peer analysis of Celldex Therapeutics could also be used in its relative valuation, which is a method of valuing Celldex Therapeutics by comparing valuation metrics with similar companies.

Peers

Celldex Therapeutics Related Equities

BCABBioatla   12.95   
0%
100.0%
ALXOAlx Oncology   9.30   
0%
71.0%
SWTXSpringWorks Therapeutics   7.49   
0%
57.0%
VTYXVentyx Biosciences   6.94   
0%
53.0%
ANABAnaptysBio   5.20   
0%
40.0%
KROSKeros Therapeutics   3.86   
0%
29.0%
CYTKCytokinetics   3.00   
0%
23.0%
DAWNDay One   2.85   
0%
22.0%
AVTEAerovate Therapeutics   1.92   
0%
14.0%
COGTCogent Biosciences   1.67   
0%
12.0%
RNAAvidity Biosciences   1.62   
0%
12.0%
IDYAIdeaya Biosciences   0.71   
0%
5.0%
EWTXEdgewise Therapeutics   0.69   
0%
5.0%
MGTXMeiraGTx Holdings   0.17   
0%
1.0%
IMTXImmatics   0.13   
0%
1.0%
RVMDRevolution Medicines   0.05   
1.0%
0%
TVTXTravere Therapeutics   0.05   
1.0%
0%
DYNDyne Therapeutics   0.13   
1.0%
0%
CRNXCrinetics Pharmaceuticals   1.70   
13.0%
0%

Additional Tools for Celldex Stock Analysis

When running Celldex Therapeutics' price analysis, check to measure Celldex Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Celldex Therapeutics is operating at the current time. Most of Celldex Therapeutics' value examination focuses on studying past and present price action to predict the probability of Celldex Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Celldex Therapeutics' price. Additionally, you may evaluate how the addition of Celldex Therapeutics to your portfolios can decrease your overall portfolio volatility.